AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listing, of claims in the application:

Listing of Claims:

1. (Currently Amended) A matrix with a bioactive component containing phospholipid, the matrix being encapsulated and containing 10 [[15]] to 40 % by weight phosphatidyl serine and 1 to 90% by weight phosphatidyl choline as the bioactive component, and 1 to 94% by weight of at least one further matrix component, the further matrix component including a fat component, a wax component, and optionally, a polyol component and physiologically compatible additive to provide the matrix with ~~selected from the group consisting of~~ 20 to 50 weight percent fat component, 5 to 20 weight percent wax component, and optionally 2 to 20 weight percent polyalcohol component, 1 to 5 weight percent physiologically compatible additive, ~~and combinations thereof~~ the fat component and the wax component both forming a part of the matrix component.

2. (Currently Amended) The matrix as claimed in claim 1, wherein the bioactive component contains 15 [[10]] to 30% by weight of phosphatidyl serine.

3. (Previously Presented) The matrix as claimed in claim 1, wherein the bioactive component contains 2.0 to 20% by weight of phosphatidyl choline.

4. (Canceled)

5. (Currently Amended) The matrix as claimed in claim 1, wherein the matrix contains:

a fat component selected from the group consisting of refined, hydrogenated, fractionated fat, and combinations thereof,

a wax component selected from the group consisting of bee wax, candellila wax, shellac, paraffin, monoglycerides, diglycerides, and combinations thereof,

a polyalcohol component selected from the group consisting of polyethylene glycol, polysorbate, polyglycerol esters, sugar esters, sorbitan esters, and combinations thereof, and

physiologically compatible additive selected from the group consisting of tocopherols, ~~derivatives of tocopherols,~~ tocotrienols, ~~derivatives of tocotrienols,~~ polycosanols, ~~derivatives of polycosanols,~~ vitamins, ~~derivatives of vitamins,~~ amino acids, phytosterols, ~~derivatives of phytosterols,~~ (poly)phenolic compounds, ~~derivatives of (poly)phenolic compounds,~~ phenolic acids, coumarins, (iso)flavonoidslignans, lignins, tannin, saponins, mono-, sesqui- and di-terpenes, carotinoids, glucosinolates, roughage, extracts of vegetable and/or animal origin, physiologically active proteins, glycolipids, mineral components, and combinations thereof.

6. (Currently Amended) The matrix as claimed in claim 1, wherein the matrix is encapsulated ~~coated~~ with a water-containing coating.

7. (Currently Amended) The matrix as claimed in claim 6, wherein the coating ~~coat~~ has a water content of 1.0 to 10.0% by weight based on total coating.

8. (Previously Presented) The matrix as claimed in claim 6, wherein the coating comprises a coating component selected from the group consisting of gelatin, glycerol, sugar (alcohols), starch, polysaccharides and mixtures thereof.

9. (Previously Presented) The matrix as claimed in claim 8, wherein the coating comprises sugar (alcohols) and polysaccharide, wherein the sugar (alcohol) comprises sorbitol and the polysaccharide is selected from the group consisting of carrageenans, alginates, pectins,

and mixtures thereof.

10. (Previously Presented) The matrix as claimed in claim 8, wherein the coating further comprises an additive selected from the group consisting of silicon dioxide, calcium carbonate, dyes that are suitable for foods, colour pigments, talcum, and combinations thereof.

11. (Previously Presented) The matrix as claimed in claim 6, wherein the weight ratio of the coating to bioactive component is 1:0.25 to 10.0.

12. (Previously Presented) The matrix as claimed in claim 1, having a total diameter of 0.3 to 20 mm.

13. (Canceled)

14. (Canceled)

15. (Previously Presented) A method for strengthening ability to cope with mental and/or physical stress and functional capacity, for improving well-being, for promoting and/or preserving health and for preventing elevated levels of serum cholesterol in a subject, comprising the steps of: a) providing a matrix as claimed in claim 1; b) producing a pharmaceutical preparation comprising the matrix; and c) administering an effective amount of the pharmaceutical preparation to the subject.

16. (Previously Presented) The matrix as claimed in claim 1, wherein the bioactive component contains 15 to 30% by weight of phosphatidyl serine.

17. (Canceled)

18. (Previously Presented) The matrix as claimed in claim 6, wherein the weight ratio of the coating to bioactive component is 1:1 to 5.0.

19. (Previously Presented) The matrix as claimed in claim 5, wherein the fat component comprises fatty acids selected from the group consisting of docosahexaenoic acid, arachidonic acid, eicosapentaenoic acid, conjugated linolenic acid, and mixtures thereof.

20. (Currently Amended) A matrix with a bioactive component containing phospholipid, the matrix comprising a bioactive component consisting essentially of 10 **[[**15**]]** to 40 % by weight phosphatidyl serine and 1 to 90% by weight phosphatidyl choline, and the matrix further comprising 1 to 94% by weight of at least one further matrix component including a fat component, a wax component, and optionally, a polyol component and physiologically compatible additive to provide the matrix with, ~~the further matrix component selected from the group consisting of~~ 20 to 50 weight percent fat component, 5 to 20 weight percent wax component, and optionally 2 to 20 weight percent polyalcohol component, 1 to 5 weight percent physiologically compatible additive, and combinations thereof, wherein the bioactive component and the further matrix component are in amounts and ratios which are effective to (a) make the bioactive component containing matrix solid or paste-like at room temperature and (b) provide the bioactive component containing matrix with the property of shear dilution, the fat component and the wax component both forming a part of the matrix component.

21. (Currently Amended) A method for providing a stable pharmaceutical preparation which includes phospholipids, the method comprising:

providing a matrix comprising a bioactive component which includes 10 **[[**15**]]** to 40 % by weight phosphatidyl serine and 1 to 90% by weight phosphatidyl choline, and 1 to 94% by weight of at least one further matrix component including a fat component, a wax component, and optionally, a polyol component and physiologically compatible additive to provide the

matrix with~~, the further matrix component selected from the group consisting of~~ 20 to 50 weight percent fat component, 5 to 20 weight percent wax component, 2 to 20 weight percent polyalcohol component, 1 to 5 weight percent physiologically compatible additive, and combinations thereof; and

~~balancing the amount of bioactive component and the further matrix component in an amounts and ratios which are effective to (a) make the bioactive component containing matrix solid or paste-like at room temperature and (b) provide the bioactive component containing matrix with the property of shear dilution~~ characterized in that the solid portion of triglyceride that can be determined by TLC is › 80% at 23°C, and the fat component and the wax component both forming a part of the matrix component .

22. (Currently Amended) A matrix with a bioactive component containing phospholipid, the matrix containing 10 **[[**15**]]** to 40 % by weight phosphatidyl serine and 1 to 90% by weight phosphatidyl choline as the bioactive component, and 1 to 94% by weight of at least one further matrix component including a fat component, a wax component, and optionally, a polyol component and physiologically compatible additive to provide the matrix with~~, the further matrix component selected from the group consisting of~~ 20 to 50 weight percent fat component, 5 to 20 weight percent wax component, 2 to 20 weight percent polyalcohol component, 1 to 5 weight percent physiologically compatible additive, and combinations thereof, wherein the at least one further matrix component is effective to (a) make the ~~the~~ bioactive component containing matrix solid or paste-like at room temperature and (b) provide the bioactive component containing matrix with the property of shear dilution, the fat component and the wax component both forming a part of the matrix component.

23. (Currently Amended) The matrix as claimed in claim 22, wherein the bioactive component contains 15 **[[**10**]]** to 30% by weight of phosphatidyl serine and 2.0 to 20% by weight of phosphatidyl choline.

24. (Currently Amended) The matrix as claimed in claim 22, wherein the matrix is encapsulated ~~coated~~ with a water-containing coating, the coating comprising a coating component selected from the group consisting of gelatin, glycerol, sugar (alcohols), starch, polysaccharides and mixtures thereof.